本帖最后由 老马 于 2012-1-13 21:20 编辑
- ~8 u7 K4 @& f/ w! Y+ b+ O' H0 f7 \3 \% f1 z3 Y
爱必妥和阿瓦斯丁的比较) y, Z# ^, h- g' L' k
. b0 \) R+ ?" \+ J$ G+ B Phttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
. o& R4 |5 Q' _9 d
& u( W/ k& Z2 \: j) q# K
+ L2 B7 R2 N8 B3 o5 u9 {http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
- \* T1 {9 J7 O& z3 K/ @5 v( m( B==================================================
8 i+ j4 z% k0 ~5 D( F2 mOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
3 u k. w( O6 [2 c+ IPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
4 g4 X3 J! J: i: eResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
; D+ S$ P# i& q/ `" P! J: |
|